KR101943889B1 - Process of preparing β-keto sulfones using xanthate compounds - Google Patents
Process of preparing β-keto sulfones using xanthate compounds Download PDFInfo
- Publication number
- KR101943889B1 KR101943889B1 KR1020170089216A KR20170089216A KR101943889B1 KR 101943889 B1 KR101943889 B1 KR 101943889B1 KR 1020170089216 A KR1020170089216 A KR 1020170089216A KR 20170089216 A KR20170089216 A KR 20170089216A KR 101943889 B1 KR101943889 B1 KR 101943889B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- added
- reaction
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
- C07C329/02—Monothiocarbonic acids; Derivatives thereof
- C07C329/04—Esters of monothiocarbonic acids
- C07C329/06—Esters of monothiocarbonic acids having sulfur atoms of thiocarbonic groups bound to acyclic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 신규한 잔테이트 화합물과 올레핀 화합물을 사용하여 β-케토 설폰 화합물을 제조하는 방법에 관한 것이다. 본 발명에 따르면 β-케토 설폰 화합물을 상업적 및 합성적으로 용이하게 입수 가능한 물질들을 사용하여 용이하게 고수율로 제조할 수 있다.The present invention relates to a method for producing a? -Ketosulfone compound using a novel zwitterion compound and an olefin compound. According to the present invention, a? -Ketosulfone compound can be easily produced in a high yield using commercially available and synthetically easily available materials.
Description
본 발명은 잔테이트 화합물을 이용한 β-케토 설폰 화합물의 제조방법에 관한 것으로, 보다 구체적으로 신규한 잔테이트 화합물과 올레핀 화합물을 출발물질로 사용하여 β-케토 설폰 화합물을 제조하는 방법, 이를 위한 신규한 잔테이트 화합물 및 이의 제조방법에 관한 것이다.More particularly, the present invention relates to a method for producing a? -Ketosulfone compound using a novel zwitterion compound and an olefin compound as starting materials, And a method for producing the same.
β-케토 설폰 화합물은 합성에서의 다양한 용도 때문에 유기합성에서 매우 중요한 화합물이다. 예를 들면, β-케토 설폰은 알켄, 알카인, 케톤 및 헤테로고리 화합물의 합성에서 핵심적인 중간체로 사용되고 있는 중요한 화합물이다. 또한, β-케토 설폰 화합물이 항진균성[참고문헌: Wolf, W. M. J. Mol . Struct . 1999, 474, 113] 및 항균성[참고문헌: Curti, C; Laget, M.; Carle, A. O.; Gellis, A.; Vanelle, P. Eur . J. Med . Chem., 2007, 42, 880]의 생물학적 활성을 갖는 것으로 알려져 있으며, 이외에도 최근에는 11β-히드록시스테로이드 디하이드로지나제 타입 I (11β-HSD1)의 저해제로서의 생화학적인 활성을 갖는 것으로 보고되고 있다[참고문헌: Xiang, J; Ipek, M.; Suri, V.; Tam, M.; Xing, Y.; Huang, N.; Zhang, Y.; Tobin, J.; Mansour, T. S.; Mckew, J. Bioorg . Med . Chem. 2007, 17, 4396].[beta] -ketosulfone compounds are very important compounds in organic synthesis due to their diverse use in synthesis. For example, β-ketosulfone is an important compound used as a key intermediate in the synthesis of alkenes, alkenes, ketones and heterocyclic compounds. In addition, the? -Ketosulfone compound has antifungal properties [Wolf, WM J. Mol . Struct . 1999 , 474 , 113] and antimicrobial activity (Curti, C; Laget, M .; Carle, AO; Gellis, A .; Vanelle, P. Eur . J. Med . Chem ., 2007 , 42 , 880], and recently it has been reported that it has biochemical activity as an inhibitor of 11? -Hydroxysteroid dehydrogenase Type I (11? -HSD1) Reference literature: Xiang, J; Ipek, M .; Suri, V .; Tam, M .; Xing, Y .; Huang, N .; Zhang, Y .; Tobin, J .; Mansour, TS; Mckew, J. Bioorg . Med . Chem . 2007 , 17 , 4396].
따라서, β-케토 설폰의 다양한 합성법들이 문헌에 보고되어 있는데, 예를 들면, 말단 알카인(terminal alkyne)과 설핀산(sulfinic acid)을 산소와 반응시켜 산화적 라디칼 반응(oxidative radical process)에 의하여 β-케토 설폰을 합성하거나, 또는 알켄과 설포닐 하이드라자이드를 촉매량의 CF3CO2H 존재 하에서 산소와 반응시켜 β-케토 설폰을 합성하는 방법이 문헌에 보고되어 있다[참고문헌: Lu, O.; Zhang, J.; Zhao, G.; Qi, Y.; Wang, H.; Lei, A. J. Am . Chem . Soc. 2013, 135, 11481; Liu, C.; Ding, L.; Guo, G.; Liu, W. Eur . J. Org . Chem . 2016, 910].Thus, various synthetic methods for? -Ketosulfone have been reported in the literature, for example, by reacting a terminal alkyne and a sulfinic acid with oxygen to form an oxidative radical process a method of synthesizing? -ketosulfone or a method of synthesizing? -ketosulfone by reacting an alkene and a sulfonyl hydrazide with oxygen in the presence of a catalytic amount of CF 3 CO 2 H has been reported in literature (refer to Lu, O .; Zhang, J .; Zhao, G .; Qi, Y .; Wang, H .; Lei, A. J. Am . Chem . Soc . 2013 , 135 , 11481; Liu, C .; Ding, L .; Guo, G .; Liu, W. Eur . J. Org . Chem . 2016 , 910].
그러나, 이들 합성법들은 일반적으로 기질의 적용범위가 한정되거나 혹은 출발물질을 상업적으로 구입하기 어렵거나 또는 격렬한 반응 조건을 필요로 하는 등의 단점들이 있다. 따라서, 상업적으로 염가에 구입할 수 있는 출발물질을 사용하여 올레핀 화합물로부터 온화한 반응 조건에서 β-케토 설폰을 제조할 수 있는 새로운 합성법의 개발이 필요하다.However, these synthetic methods generally have disadvantages such as limited range of substrates or difficulty in purchasing starting materials commercially, or requiring vigorous reaction conditions. Therefore, there is a need for the development of a new synthetic method that can produce beta -ketosulfone from olefinic compounds under mild reaction conditions using commercially available starting materials.
본 발명의 한 목적은 신규한 잔테이트 화합물과 올레핀 화합물을 사용하여 β-케토 설폰 화합물을 제조하는 방법을 제공하는 것이다.It is an object of the present invention to provide a method for producing a? -Ketosulfone compound using a novel zwitterion compound and an olefin compound.
본 발명의 다른 목적은 β-케토 설폰 화합물의 제조를 위한 신규한 잔테이트 화합물을 제공하는 것이다.Another object of the present invention is to provide a novel zonate compound for the production of [beta] -ketosulfone compounds.
본 발명의 또 다른 목적은 상기 잔테이트 화합물의 제조방법을 제공하는 것이다.It is a further object of the present invention to provide a process for preparing the abovementioned zantite compounds.
본 발명의 일 실시형태는 신규한 잔테이트 화합물과 올레핀 화합물을 이용한 하기 화학식 3의 β-케토 설폰 화합물의 제조방법에 관한 것으로서, 본 발명의 제조방법은One embodiment of the present invention relates to a process for producing a? -Ketosulfone compound represented by the following formula (3) using a novel zirconate compound and an olefin compound,
(i) 하기 화학식 1의 잔테이트 화합물을 하기 화학식 2의 올레핀 화합물과 부가반응시켜 하기 화학식 7의 잔테이트 부가물을 수득하는 단계; 및(i) subjecting a zertate compound of the formula (1) to an addition reaction with an olefin compound of the formula (2) to obtain a zertate adduct of the formula (7) And
(ii) 하기 화학식 7의 잔테이트 부가물을 라디칼 환원반응시키는 단계를 포함한다.(ii) subjecting the azide adduct of the formula (7) to a radical reduction reaction.
[화학식 1][Chemical Formula 1]
[화학식 2](2)
[화학식 7](7)
[화학식 3](3)
상기 식에서, In this formula,
Xa는 -SC(=S)OEt이고,Xa is -SC (= S) OEt,
R1은 C1-C6의 알킬기 또는 아릴기이며,R 1 is a C 1 -C 6 alkyl or aryl group,
R2는 C1-C6의 알킬기, 아릴기, 아릴옥시기, -OCOR3 또는 -R4COR5이고,R 2 is a C 1 -C 6 alkyl group, an aryl group, an aryloxy group, -OCOR 3 or -R 4 COR 5 ,
R3, R4 및 R5는 각각 독립적으로 C1-C6의 알킬기이다.R 3 , R 4 and R 5 are each independently a C 1 -C 6 alkyl group.
본 명세서에서 사용되는 C1-C6의 알킬기는 탄소수 1 내지 6개로 구성된 직쇄형 또는 분지형의 탄화수소를 의미하며, 예를 들어 메틸, 에틸, n-프로필, i-프로필, n-부틸, i-부틸, t-부틸, n-펜틸, n-헥실 등이 포함되나 이에 한정되는 것은 아니다.As used herein, the C 1 -C 6 alkyl group means a linear or branched hydrocarbon group having 1 to 6 carbon atoms such as methyl, ethyl, n -propyl, i -propyl, n -butyl, i -Butyl, t -butyl, n -pentyl, n -hexyl, and the like.
본 명세서에서 사용되는 아릴기는 아로메틱기와 헤테로아로메틱기 및 그들의 부분적으로 환원된 유도체를 모두 포함한다. 상기 아로메틱기는 5 내지 15각형으로 이루어진 단순 또는 융합 고리형이며, 헤테로아로메틱기는 산소, 황 또는 질소를 하나 이상 포함하는 아로메틱기를 의미한다. 대표적인 아릴기의 예로는 페닐, 나프틸, 피리디닐(pyridinyl), 퓨라닐(furanyl), 티오페닐(thiophenyl), 인돌릴(indolyl), 퀴놀리닐(quinolinyl), 이미다졸리닐(imidazolinyl), 옥사졸릴(oxazolyl), 티아졸릴(thiazolyl), 테트라히드로나프틸 등이 있으나 이에 한정되는 것은 아니다.As used herein, an aryl group includes both an aromatic group and a heteroaromatic group and a partially reduced derivative thereof. The arometric group is a simple or fused ring group of 5 to 15-ary, and the heteroaromatic group means an arometric group containing at least one of oxygen, sulfur or nitrogen. Representative aryl groups include, but are not limited to, phenyl, naphthyl, pyridinyl, furanyl, thiophenyl, indolyl, quinolinyl, imidazolinyl, But are not limited to, oxazolyl, thiazolyl, tetrahydronaphthyl, and the like.
본 명세서에서 사용되는 아릴옥시기는 아릴기에 단일결합된 산소 작용기를 의미하며, 페녹시, 벤질옥시 등이 포함되나 이에 한정되는 것은 아니다.As used herein, an aryloxy group means an oxygen functional group that is mono-bonded to an aryl group, and includes, but is not limited to, phenoxy, benzyloxy, and the like.
상기 C1-C6의 알킬기, 아릴기 및 아릴옥시기는 한 개 또는 그 이상의 수소가 C1-C6의 알킬기, C2-C6의 알케닐기, C2-C6의 알키닐기, C3-C10의 시클로알킬기, C3-C10의 헤테로시클로알킬기, C3-C10의 헤테로시클로알킬옥시기, C1-C6의 할로알킬기, C1-C6의 알콕시기, C1-C6의 티오알콕시기, 아릴기, 아실기, 히드록시, 티오(thio), 할로겐, 아미노, 알콕시카보닐, 카복시, 카바모일, 시아노, 니트로 등으로 치환될 수 있다.The C 1 -C 6 alkyl, aryl and aryloxy groups may be substituted by one or more of the hydrogens selected from the group consisting of C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 cycloalkyl group -C 10, C 3 -C 10 a heterocycloalkyl group, C 3 -C 10 heteroaryl cycloalkyloxy groups, C 1 -C 6 haloalkyl group, C 1 -C 6 of the alkoxy group, C 1 - C 6 thioalkoxy group, aryl group, acyl group, hydroxy, thio, halogen, amino, alkoxycarbonyl, carboxy, carbamoyl, cyano, nitro and the like.
본 발명의 일 실시형태에서, In an embodiment of the present invention,
R1은 C1-C6의 알킬기; 또는 C1-C6의 알킬기로 치환되거나 치환되지 않은 페닐이며,R 1 is a C 1 -C 6 alkyl group; Or phenyl which is unsubstituted or substituted by a C 1 -C 6 alkyl group,
R2는 C1-C6의 알킬기, 페닐, 벤질옥시, -OCOR3 또는 -R4COR5이고,R 2 is a C 1 -C 6 alkyl group, phenyl, benzyloxy, -OCOR 3 or -R 4 COR 5 ,
R3, R4 및 R5는 각각 독립적으로 C1-C6의 알킬기이다.R 3 , R 4 and R 5 are each independently a C 1 -C 6 alkyl group.
본 발명의 일 실시형태에서, In an embodiment of the present invention,
R1은 메틸; 또는 메틸로 치환되거나 치환되지 않은 페닐이며,R 1 is methyl; Or phenyl unsubstituted or substituted by methyl,
R2는 n-펜틸, 페닐, 벤질옥시, 아세톡시 또는 메틸카보닐메틸이다.R 2 is n-pentyl, phenyl, benzyloxy, acetoxy or methylcarbonylmethyl.
이하, 본 발명의 제조방법을 하기 반응식 1을 참조로 보다 상세히 설명하고자 한다. 하기에 기재된 방법은 대표적으로 사용된 방법을 예시한 것일 뿐 반응시약, 반응조건 등은 경우에 따라 얼마든지 변경될 수 있다.Hereinafter, the production method of the present invention will be described in more detail with reference to Reaction Scheme 1 below. The method described below exemplifies the representative method, but the reaction reagent, the reaction conditions, and the like may be changed as required.
[반응식 1][Reaction Scheme 1]
잔테이트 부가물 (7)은 잔테이트 화합물 (1)을 올레핀 화합물 (2)과 부가반응시켜 수득할 수 있다. 구체적으로, 잔테이트 화합물 (1)을 올레핀 화합물 (2)과 함께 라디칼 반응 조건에서 환류시키면 잔테이트 화합물 (1)에서 올레핀 화합물 (2)로 잔테이트 라디칼 전이가 일어나 잔테이트 부가물 (7)이 생성된다.Zertate adduct ( 7 ) can be obtained by the addition reaction of zertate compound ( 1 ) with olefin compound ( 2 ). Specifically, the glass Tate compound (1) an olefin compound (2) and the glass Tate radicals transferred to the olefin compound (2) from when refluxed in a radical reaction condition glass Tate compound (1) glass Tate adduct (7) up and with the .
상기 부가반응은 촉매량의 라디칼 개시제를 사용하여 수행될 수 있으며, 상기 라디칼 개시제로는 디라우로일 퍼옥사이드 (dilauroyl peroxide: DLP), 디벤조일 퍼옥사이드 (dibenzoyl peroxide: BPO), 디큐밀 퍼옥사이드 (dicumyl peroxide: CPO), 디-t-뷰틸 퍼옥사이드 (di-t-butyl peroxide: DTBP), 테트라부틸암모니움 퍼옥시디설페이트 (tetra(n-butyl)ammonium peroxydisulfate, TBAP)등이 사용될 수 있으나, 이에 한정되는 것은 아니다.The addition reaction may be carried out using a catalytic amount of a radical initiator, and examples of the radical initiator include dilauroyl peroxide (DLP), dibenzoyl peroxide (BPO), dicumyl peroxide dicumyl peroxide: CPO), di - t - butyl peroxide (di- t -butyl peroxide: DTBP) , tetrabutyl ammonium peroxydisulfate (tetra (n -butyl) ammonium peroxydisulfate , TBAP) , but such can be used, whereby But is not limited thereto.
반응용매로는 1,2-디클로로에탄 (1,2-dichloroethane: DCE), 클로로벤젠, 시클로헥산, 디이소프로필 에테르 (diisopropyl ether) 등이 사용될 수 있으나, 이에 한정되는 것은 아니다.Examples of the reaction solvent include 1,2-dichloroethane (DCE), chlorobenzene, cyclohexane, diisopropyl ether, and the like, but are not limited thereto.
이 과정에서, 잔테이트 부가물 (7)이 생성됨과 동시에 부반응 (side reaction)으로 환원적 잔테이트 이탈반응 (reductive dexanthation)이 부분적으로 일어나 소량의 β-케토 설폰 화합물 (3)이 생성될 수도 있다.In this process, a reductant dexanthation is partially caused by the side reaction at the same time that the zetate adduct 7 is produced, so that a small amount of the? -Ketosulfone compound ( 3 ) may be produced .
β-케토 설폰 화합물 (3)은 잔테이트 부가물 (7)을 라디칼 환원반응시켜 수득할 수 있다. 구체적으로, 잔테이트 부가물 (7)을 하이포아인산 (H3PO2), 트리에틸아민 (Et3N) 및 아조비스이소부티로니트릴 (AIBN)의 존재 하에 라디칼 환원반응시키면 환원적 잔테이트 이탈반응이 일어나 β-케토 설폰 화합물 (3)이 생성된다. 이때, 반응용매로는 1,4-디옥산 (1,4-dioxane), 클로로벤젠, 1,2-디클로로에탄 (1,2-dichloroethane: DCE), 디이소프로필 에테르 (diisopropyl ether) 등이 사용될 수 있으나, 이에 한정되는 것은 아니다.The? -ketosulfone compound ( 3 ) can be obtained by a radical reduction reaction of the zetate adduct ( 7 ). Specifically, the radical reduction reaction of the zetate adduct ( 7 ) in the presence of hypophosphorous acid (H 3 PO 2 ), triethylamine (Et 3 N) and azobisisobutyronitrile (AIBN) The reaction occurs to produce the? -Ketosulfone compound ( 3 ). At this time, examples of the reaction solvent include 1,4-dioxane, chlorobenzene, 1,2-dichloroethane (DCE), diisopropyl ether, etc. But is not limited thereto.
상기 라디칼 환원반응은 라디칼 개시제로서 DLP를 사용하여 i-프로필알코올 (IPA) 용매 속에서 환류하여 수행될 수도 있으나, 반응용매로 i-프로필알코올 (IPA)이 한정되는 것은 아니다.The radical reduction reaction may be carried out by refluxing in i -propyl alcohol (IPA) solvent using DLP as a radical initiator, but i -propyl alcohol (IPA) is not limited as a reaction solvent.
본 발명의 또 다른 실시형태는 신규한 잔테이트 화합물인 하기 화학식 1의 잔테이트 화합물에 관한 것이다.Yet another embodiment of the present invention relates to a novel zwitterionic compound,
[화학식 1] [Chemical Formula 1]
상기 식에서, In this formula,
Xa는 -SC(=S)OEt이고,Xa is -SC (= S) OEt,
R1은 C1-C6의 알킬기 또는 아릴기이다.R 1 is a C 1 -C 6 alkyl or aryl group.
본 발명의 잔테이트 화합물은 상기 화학식 3의 β-케토 설폰 화합물을 제조하기 위한 출발물질로 유용하게 사용될 수 있다.The quaternate compound of the present invention can be usefully used as a starting material for preparing the? -Ketosulfone compound of the above formula (3).
본 발명의 또 다른 실시형태는 상기 화학식 1의 잔테이트 화합물의 제조방법에 관한 것으로, 본 발명의 제조방법은 Another embodiment of the present invention relates to a process for preparing a zirconate compound of formula 1,
하기 화학식 4의 1,3-다이클로로아세톤을 하기 화학식 5의 소듐 설피네이트 화합물 및 하기 화학식 6의 포타슘 O-에틸 잔테이트와 순차적으로 반응시키는 단계를 포함한다.Reacting the 1,3-dichloroacetone of formula (4) with a sodium sulphinate compound of formula (5) and potassium O -ethylantietate of formula (6).
[화학식 4][Chemical Formula 4]
[화학식 5][Chemical Formula 5]
[화학식 6][Chemical Formula 6]
[화학식 1][Chemical Formula 1]
상기 식에서, In this formula,
Xa는 -SC(=S)OEt이고,Xa is -SC (= S) OEt,
R1은 C1-C6의 알킬기 또는 아릴기이다.R 1 is a C 1 -C 6 alkyl or aryl group.
이하, 상기 잔테이트 화합물의 제조방법을 하기 반응식 2를 참조로 보다 상세히 설명하고자 한다. 하기에 기재된 방법은 대표적으로 사용된 방법을 예시한 것일 뿐 반응시약, 반응조건 등은 경우에 따라 얼마든지 변경될 수 있다.Hereinafter, the production method of the zanthate compound will be described in more detail with reference to Reaction Scheme 2 below. The method described below exemplifies the representative method, but the reaction reagent, the reaction conditions, and the like may be changed as required.
[반응식 2][Reaction Scheme 2]
잔테이트 화합물 (1)은 1,3-다이클로로아세톤 (4)을 소듐 설피네이트 화합물 (5) 및 포타슘 O-에틸 잔테이트 (6)와 순차적으로 반응시켜 제조할 수 있다.Zanthate compound ( 1 ) can be prepared by sequentially reacting 1,3-dichloroacetone ( 4 ) with sodium sulfinate compound ( 5 ) and potassium O-ethylantanate ( 6 ).
반응온도는 상온이 바람직하고, 반응용매로는 디메틸설폭시드 (dimethylsulfoxide, DMSO), 디메틸포름아미드 (dimethylformamide, DMF), 아세톤 등이 사용될 수 있으나, 이에 한정되는 것은 아니다.The reaction temperature is preferably room temperature, and as a reaction solvent, dimethylsulfoxide (DMSO), dimethylformamide (DMF), acetone, or the like may be used, but the present invention is not limited thereto.
상기 1,3-다이클로로아세톤 (4), 소듐 설피네이트 화합물 (5) 및 포타슘 O-에틸 잔테이트 (6)는 상업적 구입이 가능하다.The 1,3-dichloroacetone ( 4 ), the sodium sulphinate compound ( 5 ) and the potassium O-ethylantate ( 6 ) are commercially available.
본 발명의 제조방법에 따르면, β-케토 설폰 화합물을 신규한 잔테이트 화합물과 상업적 구입 및 제조가 용이한 올레핀 화합물로부터 용이하게 고수율로 제조할 수 있다.According to the production method of the present invention, the? -Ketosulfone compound can be easily produced in high yield from a novel quaternate compound and an olefin compound which is easily commercially available and easy to manufacture.
아울러, 상기 신규한 잔테이트 화합물도 상업적 구입 및 제조가 용이한 시약들을 사용하여 용이하게 고수율로 제조할 수 있다.In addition, the novel zonate compounds can be easily produced in high yield using reagents that are easy to obtain and commercially available.
이하, 실시예에 의해 본 발명을 보다 구체적으로 설명하고자 한다. 이들 실시예는 오직 본 발명을 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업자에게 있어서 자명하다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are for illustrative purpose only and that the scope of the present invention is not limited to these embodiments.
실시예Example 1: One: OO -에틸 S-[2-옥소-3-(-Ethyl S- [2-oxo-3- ( 페닐설포닐Phenylsulfonyl )프로필] )profile] 카보노디티오에이트Carbonodithioate ( ( OO -Ethyl -Ethyl SS -[2--[2- oxooxo -3-(-3- ( phenylsulfonylphenylsulfonyl )) propylpropyl ]] carbonodithioatekarbonodithioate , 1a)의 제조, 1a)
소듐 벤젠설피네이트 (Sodium benzenesulfinate) 용액 (5a, 492.5 mg, 3.0 mmol, 8 mL 건조 DMSO)을 캐눌라를 사용하여 1,3-다이클로로아세톤 (1,3-dichloroacetone) 용액 (4, 380.9 mg, 1.0 당량, 2 mL 건조 DMSO)에 가한 후 상온에서 10시간 동안 아르곤 기체 하에서 교반하였다. 이 반응 용액에 다시 포타슘 O-에틸 잔테이트 (potassium O-ethyl xanthate) (6, 480.9 mg, 1.0 당량)를 첨가하고 상온에서 다시 4시간 동안 교반한 다음 얻어진 반응 용액에 CH2Cl2 (30 mL)와 H2O (25 mL)를 가하고 흔들어 준 다음 분액깔대기를 사용하여 하부의 유기층을 분리하였다. 상부의 수용액층을 다시 CH2Cl2 (10 mL x 2)로 더 추출하고 분리된 유기층을 전부 합한 후 포화 NaCl 수용액 (15 mL x 3)으로 세척하였다. 얻어진 유기층을 무수 MgSO4 (5 g)로 처리하고 여과 후 감압 하에서 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: CH2Cl2/헥산 = 10/1)로 정제하여 순수한 표제 화합물 (1a, 601.8 mg, 63%)을 수득하였다.Sodium benzenesulfinate solution ( 5a , 492.5 mg, 3.0 mmol, 8 mL dry DMSO) was dissolved in 1,3-dichloroacetone using a canola. solution ( 4 , 380.9 mg, 1.0 eq., 2 mL dry DMSO) and stirred at room temperature for 10 hours under argon gas. Potassium back to the reaction solution O - ethyl lactate glass (potassium O -ethyl xanthate) was added (6, 480.9 mg, 1.0 eq) and stirred for another 4 hours at room temperature, CH 2 Cl 2 in the resulting reaction solution (30 mL) and H 2 O (25 mL) were added and shaken, and the lower organic layer was separated using a separatory funnel. The upper aqueous layer was further washed with CH 2 Cl 2 (10 mL x 2) and the combined organic layers were washed with saturated aqueous NaCl solution (15 mL x 3). The obtained organic layer over anhydrous MgSO 4 (5 g) and treated to remove the solvent under reduced pressure, filtered and the obtained residue was purified by flash column chromatography (silica gel:: Merck 70-230, mobile phase CH 2 Cl 2 / hexane = 10/1) pure title Compound ( 1a , 601.8 mg, 63%) was obtained.
1H NMR (CDCl3, 400 MHz) δ 1.40 (t, J = 7.2 Hz, 3 H), 4.19 (s, 2 H), 4.42 (s, 2 H), 4.60 (q, J = 7.2 Hz, 2 H), 7.55-7.94 (m, 5 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.40 (t, J = 7.2 Hz, 3 H), 4.19 (s, 2 H), 4.42 (s, 2 H), 4.60 (q, J = 7.2 Hz, 2 H), 7.55-7.94 (m, 5 H).
실시예Example 2: 2: O O -에틸 S-{3-[(4--Ethyl S- {3 - [(4- 메틸페닐Methylphenyl )) 설포닐Sulfonyl ]-2-]-2- 옥소프로필Oxopropyl } } 카보노디티오에Carbonodithio 이트 (It OO -- EthylEthyl SS -{3-[(4-- {3 - [(4- methylphenyl메틸 피닐 )) sulfonylulfonyl ]-2-]-2- oxopropyl옥시opropyl }} carbonodithioatekarbonodithioate , 1b)의 제조, 1b)
소듐 p-톨루엔설피네이트 (Sodium p-toluenesulfinate) 용액 (5b, 534.5 mg, 3.00 mmol, 8 mL 건조 DMSO)을 캐눌라를 사용하여 1,3-다이클로로아세톤 (1,3-dichloroacetone) 용액 (4, 380.9 mg, 1.0 당량, 2 mL 건조 DMSO)에 가한 후 상온에서 10시간 동안 아르곤 기체 하에서 교반하였다. 이 반응 용액에 다시 포타슘 O-에틸 잔테이트 (potassium O-ethyl xanthate) (6, 480.9 mg, 1.0 당량)를 첨가하고 상온에서 다시 4시간 동안 교반한 다음 얻어진 반응 용액에 CH2Cl2 (30 mL)와 H2O (25 mL)를 가하고 흔들어 준 다음 분액깔대기를 사용하여 하부의 유기층을 분리하였다. 상부의 수용액층을 다시 CH2Cl2 (10 mL x 2)로 더 추출하고 분리된 유기층을 전부 합한 후 포화 NaCl 수용액 (15 mL x 3)으로 세척하였다. 얻어진 유기층을 무수 MgSO4 (5 g)로 처리하고 여과한 후 감압 하에서 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: CH2Cl2/헥산 = 8/1)로 정제하여 순수한 표제 화합물 (1b, 598.5 mg, 60%)을 수득하였다.Sodium p - toluene sulfinate (Sodium p -toluenesulfinate) solution (5b, 534.5 mg, 3.00 mmol , 8 mL dry DMSO) to cache using Cronulla 1, 3-dichloroacetone (1,3-dichloroacetone) solution ( 4 , 380.9 mg, 1.0 eq., 2 mL dry DMSO) and stirred at room temperature for 10 hours under argon gas. Potassium back to the reaction solution O - ethyl lactate glass (potassium O -ethyl xanthate) was added (6, 480.9 mg, 1.0 eq) and stirred for another 4 hours at room temperature, CH 2 Cl 2 in the resulting reaction solution (30 mL) and H 2 O (25 mL) were added and shaken, and the lower organic layer was separated using a separatory funnel. The upper aqueous layer was further washed with CH 2 Cl 2 (10 mL x 2) and the combined organic layers were washed with saturated aqueous NaCl solution (15 mL x 3). The obtained organic layer over anhydrous MgSO 4 (5 g) processed and filtered and the column and the residue obtained by removing the solvent under reduced pressure was purified by flash chromatography (silica gel: Merck 70-230, mobile phase: CH 2 Cl 2 / hexane = 8/1) to give pure The title compound ( 1b , 598.5 mg, 60%) was obtained.
1H NMR (CDCl3, 400 MHz) δ 1.41 (t, J = 7.2 Hz, 3 H), 2.46 (s, 3 H), 4.20 (s, 2 H), 4.39 (s, 2 H), 4.61 (q, J = 7.2 Hz, 2 H), 7.38 (d, J = 8.2 Hz, 2 H) 7.78 (d, J = 8.2 Hz, 2 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.41 (t, J = 7.2 Hz, 3 H), 2.46 (s, 3 H), 4.20 (s, 2 H), 4.39 (s, 2 H), 4.61 ( q, J = 7.2 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H) 7.78 (d, J = 8.2 Hz, 2H).
실시예Example 3: 3: OO -에틸 S-[3-(-Ethyl S- [3- ( 메틸설포닐Methylsulfonyl )-2-)-2- 옥소프로필Oxopropyl ] 카보노디티오에이트(] Carbonodithioate ( OO -Ethyl -Ethyl SS -[3-(- [3- ( methylsulfonylmethylsulfonyl )-2-)-2- oxopropyl옥시opropyl ]] carbonodithioatekarbonodithioate , 1c)의 제조, 1c)
소듐 메탄설피네이트 (Sodium methanesulfinate) 용액 (5c, 306.3 mg, 3.00 mmol, 8 mL 건조 DMSO)을 캐눌라를 사용하여 1,3-다이클로로아세톤 (1,3-dichloroacetone) 용액 (4, 380.9 mg, 1.0 당량, 2 mL 건조 DMSO)에 가한 후 상온에서 10시간 동안 아르곤 기체 하에서 교반하였다. 이 반응 용액에 다시 포타슘 O-에틸 잔테이트 (potassium O-ethyl xanthate) (6, 480.9 mg, 1.0 당량)를 첨가하고 상온에서 다시 4시간 동안 교반한 다음 얻어진 반응 용액에 CH2Cl2 (30 mL)와 H2O (25 mL)를 가하고 흔들어 준 다음 분액깔대기를 사용하여 하부의 유기층을 분리하였다. 상부의 수용액층을 다시 CH2Cl2 (10 mL x 2)로 더 추출한 다음 분리된 유기층을 전부 합한 후 포화 NaCl 수용액 (15 mL x 3)으로 세척하였다. 얻어진 유기층을 무수 MgSO4 (5 g)로 처리하고 여과한 후 감압 하에서 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: CH2Cl2/EtOAc = 40/1)로 정제하여 순수한 표제 화합물 (1c, 392.2 mg, 51%)을 수득하였다.Sodium methanesulfinate solution ( 5c , 306.3 mg, 3.00 mmol, 8 mL dry DMSO) was dissolved in 1,3-dichloroacetone using a canula. solution ( 4 , 380.9 mg, 1.0 eq., 2 mL dry DMSO) and stirred at room temperature for 10 hours under argon gas. Potassium back to the reaction solution O - ethyl lactate glass (potassium O -ethyl xanthate) was added (6, 480.9 mg, 1.0 eq) and stirred for another 4 hours at room temperature, CH 2 Cl 2 in the resulting reaction solution (30 mL) and H 2 O (25 mL) were added and shaken, and the lower organic layer was separated using a separatory funnel. The upper aqueous layer was further washed with CH 2 Cl 2 (10 mL x 2), and the combined organic layers were combined and washed with saturated aqueous NaCl solution (15 mL x 3). The obtained organic layer over anhydrous MgSO 4 (5 g) processed and filtered and the column and the residue obtained by removing the solvent under reduced pressure was purified by flash chromatography (silica gel: Merck 70-230, mobile phase: CH 2 Cl 2 / EtOAc = 40/1) to give pure The title compound ( 1c , 392.2 mg, 51%) was obtained.
1H NMR (CDCl3, 400 MHz) δ 1.44 (t, J = 7.2 Hz, 3 H), 3.07 (s, 2 H), 4.19 (s, 2 H), 4.30 (s, 2 H), 4.65 (q, J = 7.2 Hz, 2 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.44 (t, J = 7.2 Hz, 3 H), 3.07 (s, 2 H), 4.19 (s, 2 H), 4.30 (s, 2 H), 4.65 ( q, J = 7.2 Hz, 2H).
실시예Example 4: 4: O O -에틸 S-[5-옥소-1--Ethyl S- [5-oxo-1- 페닐Phenyl -6-(-6- ( 페닐설포닐Phenylsulfonyl )) 헥산Hexane -2-일] -2 days] 카보노디티오Carbonodithio 에이트 (Eight OO -- EthylEthyl SS -[5-- [5- oxooxo -1--One- phenylphenyl -6-(-6- ( phenylsulfonylphenylsulfonyl )) hexanhexan -2-yl]carbonodithioate, 7a)의 제조-2-yl] carbonodithioate, 7a)
실시예 1에서 수득한 잔테이트 화합물 (1a, 159.2 mg, 0.5 mmol) 및 알릴벤젠 (allylbenzene) (2a, 66.2 μL, 1.0 당량)을 함유한 무수 DCE (3 mL) 용액을 아르곤 기체 하에 100℃에서 10분 동안 환류한 후 DLP (39.9 mg, 0.2 당량)를 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류하였다. 반응용액을 상온으로 냉각하고 회전 감압증발기로 용매를 제거한 후 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 3/1)로 정제하여 순수한 표제 화합물 (7a, 172.5 mg, 79%)을 수득하였다.Anhydrous DCE (3 mL) solution containing the minor acid compound ( 1a , 159.2 mg, 0.5 mmol) obtained in Example 1 and allylbenzene ( 2a , 66.2 μL, 1.0 eq.) Was heated at 100 ° C. After refluxing for 10 min, DLP (39.9 mg, 0.2 eq.) Was added and refluxed under argon for 1 h. The reaction solution was cooled to room temperature and the solvent was removed using a rotary evaporator. The resulting residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 3/1) to give pure title compound 7a , 172.5 mg, 79%).
1H NMR (CDCl3, 400 MHz) δ 1.42 (t, J = 7.2 Hz, 3 H), 1.69-1.81 (m, 1 H), 1.98-2.08 (m, 1 H), 2.72-2.97 (m, 3 H), 3.14 (dd, J 1 = 14.0 Hz, J 2 = 6.0 Hz, 1 H), 3.88-3.97 (m, 1 H), 4.12 (d, J = 2.4 Hz, 2 H), 4.62 (q, J = 7.2 Hz, 2 H), 7.22-7.35 (m, 5 H), 7.53-7.88 (m, 5 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.42 (t, J = 7.2 Hz, 3 H), 1.69-1.81 (m, 1 H), 1.98-2.08 (m, 1 H), 2.72-2.97 (m, 3 H), 3.14 (dd, J 1 = 14.0 Hz, J 2 = 6.0 Hz, 1H), 3.88-3.97 (m, 1H), 4.12 (d, J = 2.4 Hz, 2 H), 4.62 (q, J = 7.2 Hz, 2 H), 7.22-7.35 (m, 5 H), 7.53-7.88 (m, 5 H).
또한, 분리 과정에서 부산물로 잔테이트 작용기가 제거된 표제 화합물 (3a, 4.7 mg, 3%)을 동시에 수득하였다.Further, the title compound ( 3a , 4.7 mg, 3%), in which the zetate functional group was removed as a byproduct during the separation, was obtained at the same time.
실시예Example 5: 5: OO -에틸 S-[2-옥소-1-(-Ethyl S- [2-oxo-1- ( 페닐설포닐Phenylsulfonyl )) 운데칸Undecan -5-일] 카보노디티오에이트(-5-yl] carbonyldithioate ( OO -- EthylEthyl SS -[2--[2- oxooxo -1-(-One-( phenylsulfonylphenylsulfonyl )) undecanundecan -5--5- ylyl ]] carbonodithioatekarbonodithioate , 7b)의 제조, 7b)
실시예 1에서 수득한 잔테이트 화합물 (1a, 159.2 mg, 0.5 mmol) 및 1-옥텐 (1-octene) (2b, 78.5 μL, 1.0 당량)을 함유한 무수 DCE (3 mL) 용액을 아르곤 기체 하에 100℃에서 10분 동안 환류한 후 DLP (39.9 mg, 0.2 당량)를 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류하였다. 얻어진 반응 용액을 상온으로 냉각한 후 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 4/1)로 분리하여 순수한 표제 화합물 (7b, 157.2 mg, 73%)을 수득하였다.Anhydrous DCE (3 mL) solution containing the minor acid compound ( 1a , 159.2 mg, 0.5 mmol) obtained in Example 1 and 1-octene ( 2b , 78.5 μL, 1.0 eq) After refluxing at 100 < 0 > C for 10 min, DLP (39.9 mg, 0.2 eq) was added and refluxed under argon for 1 h. The obtained reaction solution was cooled to room temperature and the solvent was removed by a rotary evaporator. The resulting residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 4/1) to give pure title compound ( 7b , 157.2 mg, 73%).
1H NMR (CDCl3, 400 MHz) δ 0.88 (t, J = 6.8 Hz, 3 H), 1.20-1.50 (m, 11 H), 1.58-1.69 (m, 2 H), 1.75-1.87 (m, 1 H), 2.01-2.12 (m, 1 H), 2.86 (t, J = 7.2 Hz, 2 H), 3.65-3.75 (m, 1 H), 4.16 (d, J = 3.2 Hz, 2 H), 4.64 (q, J = 6.8 Hz, 2 H), 7.55-7.94 (m, 5 H). 1 H NMR (CDCl 3 , 400 MHz)? 0.88 (t, J = 6.8 Hz, 3 H), 1.20-1.50 (m, 11 H), 1.58-1.69 (m, 2 H), 1.75-1.87 1 H), 4.16 (d, J ), 2.01-2.12 (m, 1H), 2.86 (t, J = 7.2 Hz, 2H), 3.65-3.75 = 3.2 Hz, 2 H), 4.64 (q, J = 6.8 Hz, 2 H), 7.55-7.94 (m, 5 H).
또한, 분리 과정에서 부산물로 잔테이트 작용기가 제거된 표제 화합물 (3b, 4.7 mg, 3%)을 동시에 수득하였다. Further, the title compound ( 3b , 4.7 mg, 3%) in which the zetate functional group was removed as a by-product in the separation process was obtained at the same time.
실시예Example 6: 6: SS -[1-(-[One-( 벤질옥시Benzyloxy )-5-옥소-6-() -5-oxo-6- ( 페닐설포닐Phenylsulfonyl )) 헥산Hexane -2-일] -2 days] OO -에틸 -ethyl 카보노디티오에이트Carbonodithioate ( ( SS -[1-(-[One-( BenzyloxyBenzyloxy )-5-) -5- oxooxo -6-(-6- ( phenylsulfonylphenylsulfonyl )) hexanhexan -2--2- ylyl ] ] OO -- ethylethyl carbonodithioate, 7c)의 제조 carbonodithioate, 7c)
실시예 1에서 수득한 잔테이트 화합물 (1a, 159.2 mg, 0.5 mmol) 및 알릴 벤질 에테르 (allyl benzyl ether) (2c, 77.3 μL, 1.0 당량)를 함유한 무수 DCE (3 mL) 용액을 아르곤 기체 하에 100℃에서 10분 동안 환류한 후 DLP (39.9 mg, 0.2 당량)를 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류하였다. 얻어진 반응 용액을 상온으로 냉각한 후 회전감압 증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 3.5/1)로 분리하여 순수한 표제 화합물 (7c, 165.6 mg, 71%)을 수득하였다.A solution of anhydrous DCE (3 mL) containing the minor acid compound ( 1a , 159.2 mg, 0.5 mmol) obtained in Example 1 and allyl benzyl ether ( 2c , 77.3 μL, 1.0 eq) After refluxing at 100 < 0 > C for 10 min, DLP (39.9 mg, 0.2 eq) was added and refluxed under argon for 1 h. The resulting reaction solution was cooled to room temperature and the solvent was removed by rotary evaporation. The resulting residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 3.5 / 1) to give pure title compound ( 7c , 165.6 mg, 71%).
1H NMR (CDCl3, 400 MHz) δ 1.41 (t, J = 7.2 Hz, 3 H), 1.86-1.98 (m, 1 H), 2.14-2.25 (m, 1 H), 2.78-2.96 (m, 2 H), 3.58 (dd, J 1 = 9.9 Hz, J 2 = 6.6 Hz, 1 H), 3.71 (dd, J 1 = 9.9 Hz, J 2 = 4.0 Hz, 1 H), 3.89-3.98 (m, 1 H), 4.10 (s, 2 H), 4.53 (s, 2 H), 4.63 (q, J = 7.2 Hz, 2 H), 7.26-7.39 (m, 5 H), 7.53-7.90 (m, 5 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.41 (t, J = 7.2 Hz, 3 H), 1.86-1.98 (m, 1 H), 2.14-2.25 (m, 1 H), 2.78-2.96 (m, 2 H), 3.58 (dd, J 1 = 9.9 Hz, J 2 = 6.6 Hz, 1 H), 3.71 (dd, J 1 = 9.9 Hz, J 2 = 4.0 Hz, 1H), 3.89-3.98 (m, 1H), 4.10 (s, 2H), 4.53 (s, 2H), 4.63 (q, J = 7.2 Hz, 2H), 7.26-7.39 (m, 5 H), 7.53 - 7.90 (m, 5 H).
또한, 분리 과정에서 부산물로 잔테이트 작용기가 제거된 표제 화합물 (3c, 6.9 mg, 4%)을 동시에 수득하였다. Further, the title compound ( 3c , 6.9 mg, 4%), in which the zetate functional group was removed as a by-product in the separation process, was obtained at the same time.
실시예Example 7: 2-[( 7: 2 - [( 에톡시카보노티오일Ethoxycarbonyl oil )) 설파닐Sulfanyl ]-5-옥소-6-(] -5-oxo-6- ( 페닐설포닐Phenylsulfonyl )) 헥실Hexyl 아세테이트 (2-[( Acetate (2 - [( EthoxycarbonothioylEthoxycarbonothioyl )) sulfanylsulfanyl ]-5-] -5- oxooxo -6-(-6- ( phenylsulfonylphenylsulfonyl )) hexylhexyl acetate, 7d)의 제조 acetate, 7d)
실시예 1에서 수득한 잔테이트 화합물 (1a, 159.2 mg, 0.5 mmol) 및 알릴 아세테이트 (allyl acetate) (2d, 53.9 μL, 1.0 당량)를 함유한 무수 DCE (3 mL) 용액을 아르곤 기체 하에 100℃에서 10분 동안 환류한 후 DLP (39.9 mg, 0.2 당량)를 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류하였다. 얻어진 반응 용액을 상온으로 냉각한 후 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 2/1)로 분리하여 순수한 표제 화합물 (7d, 163.2 mg, 78%)을 수득하였다.Anhydrous DCE (3 mL) solution containing the minor acid compound ( 1a , 159.2 mg, 0.5 mmol) obtained in Example 1 and allyl acetate ( 2d , 53.9 μL, 1.0 eq) At reflux for 10 min, then DLP (39.9 mg, 0.2 eq) was added and refluxed under argon for another hour. The obtained reaction solution was cooled to room temperature and the solvent was removed by a rotary evaporator. The resulting residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 2/1) to give pure title compound ( 7d , 163.2 mg, 78%).
1H NMR (CDCl3, 400 MHz) δ 1.44 (t, J = 6.8 Hz, 3 H), 1.80-1.92 (m, 1 H), 2.05-2.19 (m, 4 H), 2.89-2.98 (m, 2 H), 3.92-4.00 (m, 1 H), 4.17 (s, 2 H), 4.22 (dd, J 1 = 11.5 Hz, J 2 = 6.0 Hz, 1 H), 4.30 (dd, J 1 = 11.5 Hz, J 2 = 4.6 Hz, 1 H), 4.65 (q, J = 6.8 Hz, 2 H), 7.56-7.94 (m, 5 H). 1 H NMR (CDCl 3 , 400 MHz)? 1.44 (t, J = 6.8 Hz, 3 H), 1.80-1.92 (m, 1H), 2.05-2.19 (m, 4H), 2.89-2.98 2 H), 3.92-4.00 (m, 1 H), 4.17 (s, 2 H), 4.22 (dd, J 1 = 11.5 Hz, J 2 = 6.0 Hz, 1H), 4.30 (dd, J 1 = 11.5 Hz, J 2 = 4.6 Hz, 1H), 4.65 (q, J = 6.8 Hz, 2H), 7.56-7.94 (m, 5H).
또한, 분리 과정에서 부산물로 잔테이트 작용기가 제거된 표제 화합물 (3d, 6.0 mg, 4%)을 동시에 수득하였다.Further, the title compound ( 3d , 6.0 mg, 4%) in which the zetate functional group was removed as a by-product in the separation process was obtained at the same time.
실시예Example 8: 8: OO -에틸 -ethyl SS -[2,8-- [2,8- 디옥소Dioxo -1-(-One-( 페닐설포닐Phenylsulfonyl )) 노난Nonan -5-일] -5 days] 카보노디티오에이트Carbonodithioate (( OO -- EthylEthyl SS -[2,8-- [2,8- dioxodioxo -1-(-One-( phenylsulfonylphenylsulfonyl )) nonannonan -5--5- ylyl ] ] carbonodithioatekarbonodithioate , 7e)의 제조, 7e)
실시예 1에서 수득한 잔테이트 화합물 (1a, 159.2 mg, 0.5 mmol) 및 5-헥센-2-온 (5-hexen-2-one) (2e, 58.4 μL, 1.0 당량)을 함유한 무수 DCE (3 mL) 용액을 아르곤 기체 하에 100℃에서 10분 동안 환류한 후 DLP (39.9 mg, 0.2 당량)를 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류하였다. 얻어진 반응 용액을 상온으로 냉각한 후 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 1.5/1)로 분리하여 순수한 표제 화합물 (7e, 166.6 mg, 80%)을 수득하였다.Anhydrous DCE (5 ml) containing the minor acid compound ( 1a , 159.2 mg, 0.5 mmol) obtained in Example 1 and 5-hexen-2-one ( 2e , 58.4 μL, 1.0 eq) 3 mL) was refluxed under argon gas at 100 < 0 > C for 10 min. DLP (39.9 mg, 0.2 eq) was added and refluxed for 1 h under argon gas. The obtained reaction solution was cooled to room temperature and the solvent was removed by a rotary evaporator. The resulting residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 1.5 / 1) to give pure title compound ( 7e , 166.6 mg, 80%).
1H NMR (CDCl3, 400 MHz) δ 1.43 (t, J = 7.2 Hz, 3 H), 1.76-1.92 (m, 2 H), 1.98-2.10 (m, 2 H), 2.14 (s, 3 H), 2.60 (t, J = 7.2 Hz, 2 H), 2.88 (t, J = 7.2 Hz, 2 H), 3.65-3.74 (m, 1 H), 4.16 (d, J = 1.2 Hz, 2 H), 4.64 (q, J = 7.2 Hz, 2 H), 7.56-7.92 (m, 5 H). 1 H NMR (CDCl 3 , 400 MHz)? 1.43 (t, J = 7.2 Hz, 3H), 1.76-1.92 (m, 2H), 1.98-2.10 ), 2.60 (t, J = 7.2 Hz, 2 H), 2.88 (t, J = 7.2 Hz, 2 H), 3.65-3.74 (m, 1 H), 4.16 (d, J = 1.2 Hz, 2 H), 4.64 (q, J = 7.2 Hz, 2 H), 7.56-7.92 (m, 5 H).
또한, 분리 과정에서 부산물로 잔테이트 작용기가 제거된 표제 화합물 (3e, 4.4 mg, 3%)을 동시에 수득하였다.Further, the title compound ( 3e , 4.4 mg, 3%) in which the zetate functional group was removed as a by-product in the separation process was obtained at the same time.
실시예Example 9: 9: OO -에틸 -ethyl SS -{6-[(4-- {6 - [(4- 메틸페닐Methylphenyl )) 설포닐Sulfonyl ]-5-옥소-1-] -5-oxo-1- 페닐헥산Phenyl hexane -2-일} -2 days} 카보노디티오에이트Carbonodithioate (( OO -- EthylEthyl SS -{6-[(4-- {6 - [(4- methylphenyl메틸 피닐 )) sulfonylulfonyl ]-5-] -5- oxooxo -1--One- phenylhexan파henylhexan -2-yl} -2-yl} carbonodithioatekarbonodithioate , 7f)의 제조, 7f)
실시예 2에서 수득한 잔테이트 화합물 (1b, 166.3 mg, 0.5 mmol) 및 알릴벤젠 (allylbenzene) (2a, 66.2 μL, 1.0 당량)을 함유한 무수 DCE (3 mL) 용액을 아르곤 기체 하에 100℃에서 10분 동안 환류한 후 DLP (39.9 mg, 0.2 당량)를 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류하였다. 얻어진 반응 용액을 상온으로 냉각한 후 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 3.5/1)로 분리하여 순수한 표제 화합물 (7f, 180.2 mg, 80%)을 수득하였다.Anhydrous DCE (3 mL) solution containing the minor acid compound ( 1b , 166.3 mg, 0.5 mmol) obtained in Example 2 and allylbenzene ( 2a , 66.2 μL, 1.0 eq.) Was heated at 100 ° C. After refluxing for 10 min, DLP (39.9 mg, 0.2 eq.) Was added and refluxed under argon for 1 h. The resulting reaction solution was cooled to room temperature and the solvent was removed by rotary evaporation. The resulting residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 3.5 / 1) to give pure title compound ( 7f , 180.2 mg, 80%).
1H NMR (CDCl3, 400 MHz) δ 1.42 (t, J = 7.2 Hz, 3 H), 1.68-1.80 (m, 1 H), 1.97-2.08 (m, 1 H), 2.45 (s, 3 H), 2.71-2.95 (m, 3 H), 3.14 (dd, J 1 = 14.0 Hz, J 2 = 6.0 Hz, 1 H), 3.88-3.97 (m, 1 H), 4.07 (d, J = 2.8 Hz, 2 H), 4.62 (q, J = 6.8 Hz, 2 H), 7.21-7.38 (m, 7 H), 7.71 (d, J = 8.4 Hz, 2 H). 1 H NMR (CDCl 3 , 400 MHz)? 1.42 (t, J = 7.2 Hz, 3 H), 1.68-1.80 ), 2.71-2.95 (m, 3 H), 3.14 (dd, J 1 = 14.0 Hz, J 2 = 6.0 Hz, 1H), 3.88-3.97 (m, 1H), 4.07 (d, J = 2.8 Hz, 2 H), 4.62 (q, J = 6.8 Hz, 2 H), 7.21-7.38 (m, 7 H), 7.71 (d, J = 8.4 Hz, 2 H).
또한, 분리 과정에서 부산물로 잔테이트 작용기가 제거된 표제 화합물 (3f, 6.6 mg, 4%)을 동시에 수득하였다.Further, the title compound ( 3f , 6.6 mg, 4%), in which the zetate functional group was removed as a by-product in the separation process, was obtained at the same time.
실시예Example 10: 10: OO -에틸 -ethyl SS -{1-[(4-- {1 - [(4- 메틸페닐Methylphenyl )) 설포닐Sulfonyl ]-2-]-2- 옥소운데칸Oxoundecane -5-일} -5 days} 카보노디티오에이트Carbonodithioate ( ( OO -- EthylEthyl SS -{1-[(4-- {1 - [(4- methylphenyl메틸 피닐 )) sulfonylulfonyl ]-2-]-2- oxoundecanoxoundecan -5--5- ylyl } carbonodithioate, 7g)의 제조} carbonodithioate, 7g)
실시예 2에서 수득한 잔테이트 화합물 (1b, 166.3 mg, 0.5 mmol) 및 1-옥텐 (1-octene) (2b, 78.5 μL, 1.0 당량)을 함유한 무수 DCE (2 mL) 용액을 아르곤 기체 하에 100℃에서 10분 동안 환류한 후 DLP (39.9 mg, 0.2 당량)를 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류하였다. 얻어진 반응 용액을 상온으로 냉각한 후 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 5/1)로 분리하여 순수한 표제 화합물 (7g, 182.3 mg, 82%)을 수득하였다.A solution of anhydrous DCE (2 mL) containing the minor acid compound ( 1b , 166.3 mg, 0.5 mmol) obtained in Example 2 and 1-octene ( 2b , 78.5 μL, 1.0 eq) After refluxing at 100 < 0 > C for 10 min, DLP (39.9 mg, 0.2 eq) was added and refluxed under argon for 1 h. The obtained reaction solution was cooled to room temperature and the solvent was removed by a rotary evaporator. The resulting residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 5/1) to give pure title compound ( 7 g , 182.3 mg, 82%).
1H NMR (CDCl3, 400 MHz) δ 0.88 (t, J = 7.0 Hz, 3 H), 1.20-1.47 (m, 11 H), 1.58-1.68 (m, 1 H), 1.74-1.86 (m, 1 H), 2.00-2.12 (m, 1 H), 2.47 (s, 3 H), 2.85 (t, J = 7.2 Hz, 2 H), 3.64-3.74 (m, 1 H), 4.14 (d, J = 4.0 Hz, 2 H), 4.64 (q, J = 7.0 Hz, 2 H), 7.37 (d, J = 8.4 Hz, 2 H) 7.75 (d, J = 8.4 Hz, 2 H). 1 H NMR (CDCl 3, 400 MHz) δ 0.88 (t, J = 7.0 Hz, 3 H), 1.20-1.47 (m, 11 H), 1.58-1.68 (m, 1 H), 1.74-1.86 (m, 1 H), 2.00-2.12 (m, 1 H), 2.47 (s, 3 H), 2.85 (t, J = 7.2 Hz, 2 H), 3.64-3.74 (m, 1 H), 4.14 (d, J = 4.0 Hz, 2H), 4.64 (q, J = 7.0 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H) 7.75 (d, J = 8.4 Hz, 2H).
또한, 분리 과정에서 부산물로 잔테이트 작용기가 제거된 표제 화합물 (3g, 6.5 mg, 4%)을 동시에 수득하였다.Further, the title compound ( 3 g , 6.5 mg, 4%) in which the zetate functional group was removed as a by-product in the separation process was obtained at the same time.
실시예Example 11: 11: OO -에틸 -ethyl SS -[6-(- [6- ( 메틸설포닐Methylsulfonyl )-5-옥소-1-) -5-oxo-1- 페닐헥산Phenyl hexane -2-일] -2 days] 카보노디티오에이트Carbonodithioate ( ( OO -- EthylEthyl SS -[6-(- [6- ( methylsulfonylmethylsulfonyl )-5-) -5- oxooxo -1--One- phenylhexan파henylhexan -2--2- ylyl ] carbonodithioate, 7h)의 제조] carbonodithioate, 7h)
실시예 3에서 수득한 잔테이트 화합물 (1c, 128.2 mg, 0.5 mmol) 및 알릴벤젠 (allylbenzene) (2a, 66.2 μL, 1.0 당량)을 함유한 무수 DCE (3 mL) 용액을 아르곤 기체 하에 100℃에서 10분 동안 환류한 후 DLP (39.9 mg, 0.2 당량)를 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류하였다. 얻어진 반응 용액을 상온으로 냉각한 후 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 2.5/1)로 분리하여 순수한 표제 화합물 (7h, 149.8 mg, 80%)을 수득하였다.Anhydrous DCE (3 mL) solution containing the minor acid compound ( 1c , 128.2 mg, 0.5 mmol) obtained in Example 3 and allylbenzene ( 2a , 66.2 μL, 1.0 eq.) Was stirred at 100 ° C. After refluxing for 10 min, DLP (39.9 mg, 0.2 eq.) Was added and refluxed under argon for 1 h. The obtained reaction solution was cooled to room temperature and the solvent was removed by a rotary evaporator. The resulting residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 2.5 / 1) to give pure title compound ( 7h , 149.8 mg, 80%).
1H NMR (CDCl3, 400 MHz) δ 1.42 (t, J = 7.0 Hz, 3 H), 1.74-1.86 (m, 1 H), 2.04-2.18 (m, 1 H), 2.74-2.95 (m, 3 H), 3.02 (s, 3 H), 3.16 (dd, J 1 = 13.8 Hz, J 2 = 6.2 Hz, 1 H), 3.92-4.02 (m, 3 H), 4.62 (q, J = 7.0 Hz, 2 H), 7.21-7.35 (m, 5 H). One1 H NMR (CDCl 33, 400 MHz) [delta] 1.42 (t,J = 7.0 Hz, 3H), 1.74-1.86 (m, 1H), 2.04-2.18 (m, 1H), 2.74-2.95 (m, 3H), 3.02J One = 13.8 Hz,J 2 = 6.2 Hz, 1H), 3.92-4.02 (m, 3H), 4.62 (q,J = 7.0 Hz, 2 H), 7.21-7.35 (m, 5 H).
또한, 분리 과정에서 부산물로 잔테이트 작용기가 제거된 표제 화합물 (3h, 3.8 mg, 3%)을 동시에 수득하였다.Further, the title compound ( 3h , 3.8 mg, 3%), in which the zetate functional group was removed as a by-product in the separation process, was obtained at the same time.
실시예Example 12: 12: OO -에틸 -ethyl SS -[1-(-[One-( 메틸설포닐Methylsulfonyl )-2-)-2- 옥소운데칸Oxoundecane -5-일] -5 days] 카보노디티오에이트Carbonodithioate (( OO -- EthylEthyl SS -[1-(-[One-( methylsulfonylmethylsulfonyl )-2-)-2- oxoundecanoxoundecan -5--5- ylyl ] ] carbonodithioatekarbonodithioate , 7i)의 제조, 7i)
실시예 3에서 수득한 잔테이트 화합물 (1c, 128.2 mg, 0.5 mmol) 및 1-옥텐 (1-octene) (2b, 78.5 μL, 1.0 당량)을 함유한 무수 DCE (3 mL) 용액을 아르곤 기체 하에 100℃에서 10분 동안 환류한 후 DLP (39.9 mg, 0.2 당량)를 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류하였다. 얻어진 반응 용액을 상온으로 냉각한 후 회전감압 증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 3/1)로 분리하여 순수한 표제 화합물 (7i, 138.2 mg, 75%)을 수득하였다.The retardant compound obtained in Example 3 Anhydrous DCE (3 mL) solution containing 1-octene ( 1c , 128.2 mg, 0.5 mmol) and 1-octene ( 2b , 78.5 μL, 1.0 eq.) Was refluxed in an argon atmosphere at 100 ° C. for 10 min DLP (39.9 mg, 0.2 eq) was added and refluxed under argon for another hour. The obtained reaction solution was cooled to room temperature and the solvent was removed using a rotary evaporator. The resulting residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 3/1) to give pure title compound ( 7i , 138.2 mg, 75%).
1H NMR (CDCl3, 400 MHz) δ 0.88 (t, J = 6.8 Hz, 3 H), 1.28 (bs, 8 H), 1.43 (t, J = 7.0 Hz, 3 H), 1.57-1.71 (m, 2 H), 1.80-1.92 (m, 1 H), 2.08-2.19 (m, 1 H), 2.87 (t, J = 7.0 Hz, 2 H), 3.06 (s, 3 H), 3.70-3.79 (m, 1 H), 4.04 (s, 2 H), 4.64 (q, J = 7.0 Hz, 2 H). 1 H NMR (CDCl 3, 400 MHz) δ 0.88 (t, J = 6.8 Hz, 3 H), 1.28 (bs, 8 H), 1.43 (t, J = 7.0 Hz, 3 H), 1.57-1.71 (m , 2 H), 1.80-1.92 (m , 1 H), 2.08-2.19 (m, 1 H), 2.87 (t, J = 7.0 Hz, 2H), 3.06 (s, 3H), 3.70-3.79 (m, 1H), 4.04 (s, 2H), 4.64 (q, J = 7.0 Hz, 2H).
또한, 분리 과정에서 부산물로 잔테이트 작용기가 제거된 표제 화합물 (3i, 5.0 mg, 4%)을 동시에 수득하였다.In addition, the title compound ( 3i , 5.0 mg, 4%) in which the zetate functional group was removed as a by-product in the separation process was obtained at the same time.
실시예Example 13: 6- 13: 6- 페닐Phenyl -1-(-One-( 페닐설포닐Phenylsulfonyl )) 헥산Hexane -2-온 (6-One (6- PhenylPhenyl -1-(phenylsulfonyl)hexan-2-one, 3a)의 제조-1- (phenylsulfonyl) hexan-2-one, 3a)
실시예 4에서 수득한 잔테이트 부가물 (7a, 131.0 mg, 0.3 mmol)을 함유한 1,4-디옥산 (1,4-dioxane) (3 mL) 용액에 H3PO2 (164.2 μL, 5.0 당량, 50wt % in H2O) 및 Et3N (230.0 μL, 5.5 당량)을 가하고 아르곤 기체 하에서 100℃로 10분 동안 환류한 다음 반응 용액에 AIBN (29.6 mg, 0.6 당량)을 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류한 후 상온으로 냉각하였다. 반응 용액에 CH2Cl2 (20 mL)를 가하여 희석한 후 포화된 NH4Cl 수용액 (10 mL)을 가하여 흔들어 준 후 분액 깔대기로 유기층을 분리하고 상부의 수용액 층은 CH2Cl2 (10 mL)로 2회 더 추출하였다. 분리된 유기층을 전부 합한 후 무수 MgSO4로 처리하고 여과한 다음 회전 감압 증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 2.5/1)로 분리하여 표제 화합물 (3a, 75.9 mg, 80%)을 수득하였다.To a 1,4-dioxane (3 mL) solution containing the minor adduct ( 7a , 131.0 mg, 0.3 mmol) obtained in Example 4 was added H 3 PO 2 (164.2 μL, 5.0 equivalents, 50wt% in H 2 O) and Et 3 N (230.0 μL, was added to 5.5 eq.) was added AIBN (29.6 mg, 0.6 eq) to the reaction solution was refluxed for 10 minutes in 100 ℃ under an argon gas, and another 1 After refluxing under argon gas for a period of time, it was cooled to room temperature. The reaction solution was diluted with CH 2 Cl 2 (20 mL), shaken with saturated aqueous NH 4 Cl solution (10 mL), and the organic layer was separated with a separatory funnel. The upper aqueous layer was washed with CH 2 Cl 2 ). ≪ / RTI > The separated organic layers were combined and treated with anhydrous MgSO 4 , filtered, and the solvent was removed by rotary evaporation. The residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 2.5 / 1 ) To obtain the title compound ( 3a , 75.9 mg, 80%).
1H NMR (CDCl3, 400 MHz) δ 1.58-1.68 (m, 4 H), 2.61 (t, J = 7.0 Hz, 2 H), 2.73 (t, J = 6.6 Hz, 2 H), 4.12 (s, 2 H), 7.13-7.32 (m, 5 H), 7.53-7.90 (m, 5 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.58-1.68 (m, 4 H), 2.61 (t, J = 7.0 Hz, 2 H), 2.73 (t, J = 6.6 Hz, 2 H), 4.12 (s, 2 H), 7.13-7.32 (m, 5 H), 7.53-7.90 (m, 5 H).
실시예Example 14: 1-( 14: 1- ( 페닐설포닐Phenylsulfonyl )) 운데칸Undecan -2-온 (1-(One (1- ( PhenylsulfonylPhenylsulfonyl )) undecanundecan -2--2- oneone , 3b)의 제조, 3b)
실시예 5에서 수득한 잔테이트 부가물 (7b, 129.2 mg, 0.3 mmol)을 함유한 1,4-디옥산 (1,4-dioxane) (3 mL) 용액에 H3PO2 (164.2 μL, 5.0 당량, 50wt % in H2O) 및 Et3N (230.0 μL, 5.5 당량)을 가하고 아르곤 기체 하에서 100℃로 10분 동안 환류한 다음 반응 용액에 AIBN (29.6 mg, 0.6 당량)을 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류한 후 상온으로 냉각하였다. 반응 용액에 CH2Cl2 (20 mL)를 가하여 희석한 후 포화된 NH4Cl 수용액 (10 mL)을 가하여 흔들어 준 후 분액 깔대기로 유기층을 분리하고 상부의 수용액 층은 CH2Cl2 (10 mL)로 2회 더 추출하였다. 분리된 유기층을 전부 합한 후 무수 MgSO4로 처리하고 여과한 다음 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 4.5/1)로 분리하여 표제 화합물 (3b, 76.4 mg, 82%)을 수득하였다.H 3 PO 2 (164.2 μL, 5.0 mmol) was added to a 1,4-dioxane (3 mL) solution containing the minor adduct ( 7b , 129.2 mg, 0.3 mmol) obtained in Example 5 equivalents, 50wt% in H 2 O) and Et 3 N (230.0 μL, was added to 5.5 eq.) was added AIBN (29.6 mg, 0.6 eq) to the reaction solution was refluxed for 10 minutes in 100 ℃ under an argon gas, and another 1 After refluxing under argon gas for a period of time, it was cooled to room temperature. The reaction solution was diluted with CH 2 Cl 2 (20 mL), shaken with saturated aqueous NH 4 Cl solution (10 mL), and the organic layer was separated with a separatory funnel. The upper aqueous layer was washed with CH 2 Cl 2 ). ≪ / RTI > The separated organic layers were combined and treated with anhydrous MgSO 4 , filtered, and the solvent was removed by rotary evaporation. The residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 4.5 / 1 ) To obtain the title compound ( 3b , 76.4 mg, 82%).
1H NMR (CDCl3, 400 MHz) δ 0.88 (t, J = 6.8 Hz, 3 H), 1.26 (bs, 10 H), 1.50-1.62 (m, 4 H), 2.70 (t, J = 7.2 Hz, 2 H), 4.15 (s, 2 H), 7.55-7.92 (m, 5 H). 1 H NMR (CDCl 3, 400 MHz) δ 0.88 (t, J = 6.8 Hz, 3 H), 1.26 (bs, 10 H), 1.50-1.62 (m, 4 H), 2.70 (t, J = 7.2 Hz , 2 H), 4.15 (s, 2 H), 7.55-7.92 (m, 5 H).
실시예Example 15: 6-( 15: 6- ( 벤질옥시Benzyloxy )-1-()-One-( 페닐설포닐Phenylsulfonyl )) 헥산Hexane -2-온 (6-(One (6- ( BenzyloxyBenzyloxy )-1-(phenylsulfonyl)hexan-2-one, 3c)의 제조) -1- (phenylsulfonyl) hexan-2-one, 3c)
실시예 6에서 수득한 잔테이트 부가물 (7c, 140.0 mg, 0.3 mmol)을 함유한 1,4-디옥산 (1,4-dioxane) (3 mL) 용액에 H3PO2 (164.2 μL, 5.0 당량, 50wt % in H2O) 및 Et3N (230.0 μL, 5.5 당량)을 가하고 아르곤 기체 하에서 100℃로 10분 동안 환류한 다음 반응 용액에 AIBN (29.6 mg, 0.6 당량)을 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류한 후 상온으로 냉각하였다. 반응 용액에 CH2Cl2 (20 mL)를 가하여 희석한 후 포화된 NH4Cl 수용액 (10 mL)을 가하여 흔들어 준 후 분액 깔대기로 유기층을 분리하고 상부의 수용액 층은 CH2Cl2 (10 mL)로 2회 더 추출하였다. 분리된 유기층을 전부 합한 후 무수 MgSO4로 처리하고 여과한 다음 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 3/1)로 분리하여 표제 화합물 (3c, 76.9 mg, 74%)을 수득하였다.H 3 PO 2 (164.2 μL, 5.0 mmol) was added to a 1,4-dioxane (3 mL) solution containing the minor adduct ( 7c , 140.0 mg, 0.3 mmol) obtained in Example 6 equivalents, 50wt% in H 2 O) and Et 3 N (230.0 μL, was added to 5.5 eq.) was added AIBN (29.6 mg, 0.6 eq) to the reaction solution was refluxed for 10 minutes in 100 ℃ under an argon gas, and another 1 After refluxing under argon gas for a period of time, it was cooled to room temperature. The reaction solution was diluted with CH 2 Cl 2 (20 mL), shaken with saturated aqueous NH 4 Cl solution (10 mL), and the organic layer was separated with a separatory funnel. The upper aqueous layer was washed with CH 2 Cl 2 ). ≪ / RTI > The separated organic layers were combined and treated with anhydrous MgSO 4 , filtered, and the solvent was removed by rotary evaporation. The residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 3/1 ) To give the title compound ( 3c , 76.9 mg, 74%).
1H NMR (CDCl3, 400 MHz) δ 1.55-1.72 (m, 4 H), 2.73 (t, J = 7.0 Hz, 2 H), 3.46 (t, J = 6.2 Hz, 2 H), 4.11 (s, 2 H), 4.74 (s, 2 H), 7.28-7.38 (m, 5 H), 7.53-7.92 (m, 5 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.55-1.72 (m, 4 H), 2.73 (t, J = 7.0 Hz, 2 H), 3.46 (t, J = 6.2 Hz, 2 H), 4.11 (s , 2H), 4.74 (s, 2H), 7.28-7.38 (m, 5H), 7.53-7.92 (m, 5H).
실시예Example 16: 5-옥소-6-( 16: 5-oxo-6- ( 페닐설포닐Phenylsulfonyl )) 헥실Hexyl 아세테이트 (5- Acetate (5- OxoOxo -6-(phenylsulfonyl)hexyl -6- (phenylsulfonyl) hexyl acetateacetate , 3d)의 제조, 3d)
실시예 7에서 수득한 잔테이트 부가물 (7d, 125.6 mg, 0.3 mmol)을 함유한 1,4-디옥산 (1,4-dioxane) (3 mL) 용액에 H3PO2 (164.2 μL, 5.0 당량, 50wt % in H2O) 및 Et3N (230.0 μL, 5.5 당량)을 가하고 아르곤 기체 하에서 100℃로 10분 동안 환류한 다음 반응 용액에 AIBN (29.6 mg, 0.6 당량)을 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류한 후 상온으로 냉각하였다. 반응 용액에 CH2Cl2 (20 mL)를 가하여 희석한 후 포화된 NH4Cl 수용액 (10 mL)을 가하여 흔들어 준 후 분액 깔대기로 유기층을 분리하고 상부의 수용액 층은 CH2Cl2 (10 mL)로 2회 더 추출하였다. 분리된 유기층을 전부 합한 후 무수 MgSO4로 처리하고 여과한 다음 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 2/1)로 분리하여 표제 화합물 (3d, 60.0 mg, 67%)을 수득하였다.H 3 PO 2 (164.2 μL, 5.0 mmol) was added to a 1,4-dioxane (3 mL) solution containing the adduct of the residue ( 7d , 125.6 mg, 0.3 mmol) obtained in Example 7 equivalents, 50wt% in H 2 O) and Et 3 N (230.0 μL, was added to 5.5 eq.) was added AIBN (29.6 mg, 0.6 eq) to the reaction solution was refluxed for 10 minutes in 100 ℃ under an argon gas, and another 1 After refluxing under argon gas for a period of time, it was cooled to room temperature. The reaction solution was diluted with CH 2 Cl 2 (20 mL), shaken with saturated aqueous NH 4 Cl solution (10 mL), and the organic layer was separated with a separatory funnel. The upper aqueous layer was washed with CH 2 Cl 2 ). ≪ / RTI > The separated organic layers were combined and treated with anhydrous MgSO 4 , filtered, and the solvent was removed by rotary evaporation. The residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 2/1 ) To give the title compound ( 3d , 60.0 mg, 67%).
1H NMR (CDCl3, 400 MHz) δ 1.57-1.70 (m, 4 H), 2.05 (s, 3 H), 2.77 (t, J = 6.6 Hz, 2 H), 4.05 (t, J = 6.0 Hz, 2 H), 4.16 (s, 2 H), 7.56-7.92 (m, 5 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.57-1.70 (m, 4 H), 2.05 (s, 3 H), 2.77 (t, J = 6.6 Hz, 2 H), 4.05 (t, J = 6.0 Hz , 2 H), 4.16 (s, 2 H), 7.56 - 7.92 (m, 5 H).
실시예Example 17: 1-( 17: 1- ( 페닐설포닐Phenylsulfonyl )) 노난Nonan -2,8--2,8- 디온Dion (1-( (One-( PhenylsulfonylPhenylsulfonyl )) nonannonan -2,8-dione, 3e)의 제조-2,8-dione, 3e)
실시예 8에서 수득한 잔테이트 부가물 (7e, 125.0 mg, 0.3 mmol)을 함유한 1,4-디옥산 (1,4-dioxane) (3 mL) 용액에 H3PO2 (164.2 μL, 5.0 당량, 50wt % in H2O) 및 Et3N (230.0 μL, 5.5 당량)을 가하고 아르곤 기체 하에서 100℃로 10분 동안 환류한 다음 반응 용액에 AIBN (29.6 mg, 0.6 당량)을 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류한 후 상온으로 냉각하였다. 반응 용액에 CH2Cl2 (20 mL)를 가하여 희석한 후 포화된 NH4Cl 수용액 (10 mL)을 가하여 흔들어 준 후 분액 깔대기로 유기층은 분리하고 상부의 수용액 층을 다시 CH2Cl2 (10 mL)로 2회 더 추출하였다. 분리된 유기층을 전부 합한 후 무수 MgSO4로 처리하고 여과한 다음 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EOAc = 1.5/1)로 분리하여 표제 화합물 (3e, 68.5 mg, 77%)을 수득하였다.H 3 PO 2 (164.2 μL, 5.0 mmol) was added to a 1,4-dioxane (3 mL) solution containing the minor adduct ( 7e , 125.0 mg, 0.3 mmol) obtained in Example 8 equivalents, 50wt% in H 2 O) and Et 3 N (230.0 μL, was added to 5.5 eq.) was added AIBN (29.6 mg, 0.6 eq) to the reaction solution was refluxed for 10 minutes in 100 ℃ under an argon gas, and another 1 After refluxing under argon gas for a period of time, it was cooled to room temperature. The reaction solution was diluted with CH 2 Cl 2 (20 mL), and then saturated aqueous NH 4 Cl solution (10 mL) was added to shake. The organic layer was separated with a separatory funnel, and the upper aqueous layer was further washed with CH 2 Cl 2 mL). The separated organic layers were combined and treated with anhydrous MgSO 4 , filtered, and the solvent was removed by rotary evaporation. The resulting residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EOAc = ) To give the title compound ( 3e , 68.5 mg, 77%).
1H NMR (CDCl3, 400 MHz) δ 1.22-1.34 (m, 2 H), 1.53-1.64 (m, 4 H), 2.13 (s, 3 H), 2.42 (t, J = 7.2 Hz, 2 H), 2.72 (t, J = 7.4 Hz, 2 H), 4.14 (s, 2 H), 7.56-7.92 (m, 5 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.22-1.34 (m, 2 H), 1.53-1.64 (m, 4 H), 2.13 (s, 3 H), 2.42 (t, J = 7.2 Hz, 2 H), 2.72 (t, J = 7.4 Hz, 2 H), 4.14 (s, 2 H), 7.56 - 7.92 (m, 5 H).
실시예Example 18: 1-[(4- 18: 1 - [(4- 메틸페닐Methylphenyl )) 설포닐Sulfonyl ]-6-] -6- 페닐헥산Phenyl hexane -2-온 (1-[(4-Methylphenyl)sulfonyl]-6-phenylhexan-2-one, 3f)의 제조(1 - [(4-Methylphenyl) sulfonyl] -6-phenylhexan-2-one, 3f)
실시예 9에서 수득한 잔테이트 부가물 (7f, 135.2 mg, 0.3 mmol)을 함유한 1,4-디옥산 (1,4-dioxane) (3 mL) 용액에 H3PO2 (164.2 μL, 5.0 당량, 50wt % in H2O) 및 Et3N (230.0 μL, 5.5 당량)을 가하고 아르곤 기체 하에서 100℃로 10분 동안 환류한 다음 반응 용액에 AIBN (29.6 mg, 0.6 당량)을 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류한 후 상온으로 냉각하였다. 반응 용액에 CH2Cl2 (20 mL)를 가하여 희석한 후 포화된 NH4Cl 수용액 (10 mL)을 가하여 흔들어 준 후 분액 깔대기로 유기층을 분리하고 상부의 수용액 층은 CH2Cl2 (10 mL)로 2회 더 추출하였다. 분리된 유기층을 전부 합한 후 무수 MgSO4로 처리하고 여과한 다음 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 3.5/1)로 분리하여 표제 화합물 (3f, 78.3 mg, 79%)을 수득하였다.H 3 PO 2 (164.2 μL, 5.0 mmol) was added to a solution of 1,4-dioxane (3 mL) containing the minor adduct ( 7f , 135.2 mg, 0.3 mmol) obtained in Example 9 equivalents, 50wt% in H 2 O) and Et 3 N (230.0 μL, was added to 5.5 eq.) was added AIBN (29.6 mg, 0.6 eq) to the reaction solution was refluxed for 10 minutes in 100 ℃ under an argon gas, and another 1 After refluxing under argon gas for a period of time, it was cooled to room temperature. The reaction solution was diluted with CH 2 Cl 2 (20 mL), shaken with saturated aqueous NH 4 Cl solution (10 mL), and the organic layer was separated with a separatory funnel. The upper aqueous layer was washed with CH 2 Cl 2 ). ≪ / RTI > The separated organic layers were combined and then treated with anhydrous MgSO 4 , filtered, and the solvent was removed by rotary evaporation. The residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 3.5 / 1 ) To give the title compound ( 3f , 78.3 mg, 79%).
1H NMR (CDCl3, 400 MHz) δ 1.52-1.68 (m, 4 H), 2.44 (s, 3 H), 2.60 (t, J = 6.0 Hz, 2 H), 2.73 (t, J = 6.0 Hz, 2 H), 4.10 (s, 2 H), 7.12-7.38 (m, 7 H), 7.73 (d, J = 8.4 Hz, 2 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.52-1.68 (m, 4 H), 2.44 (s, 3 H), 2.60 (t, J = 6.0 Hz, 2 H), 2.73 (t, J = 6.0 Hz , 2H), 4.10 (s, 2H), 7.12-7.38 (m, 7H), 7.73 (d, J = 8.4 Hz, 2H).
실시예Example 19: 1-[(4- 19: 1 - [(4- 메틸페닐Methylphenyl )) 설포닐Sulfonyl ]] 운데칸Undecan -2-온 (1-[(4-Methylphenyl)sulfonyl]undecan-2-one, 3g)의 제조(1 - [(4-Methylphenyl) sulfonyl] undecan-2-one, 3g)
실시예 10에서 수득한 잔테이트 부가물 (7g, 133.4 mg, 0.3 mmol)을 함유한 1,4-디옥산 (1,4-dioxane) (3 mL) 용액에 H3PO2 (164.2 μL, 5.0 당량, 50wt % in H2O) 및 Et3N (230.0 μL, 5.5 당량)을 가하고 아르곤 기체 하에서 100℃로 10분 동안 환류한 다음 반응 용액에 AIBN (29.6 mg, 0.6 당량)을 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류한 후 상온으로 냉각하였다. 반응 용액에 CH2Cl2 (20 mL)를 가하여 희석한 후 포화된 NH4Cl 수용액 (10 mL)을 가하여 흔들어 준 후 분액 깔대기로 유기층을 분리하고 상부 수용액 층은 CH2Cl2 (10 mL)로 2회 더 추출하였다. 분리된 유기층을 전부 합한 후 무수 MgSO4로 처리하고 여과한 다음 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 5/1)로 분리하여 표제 화합물 (3g, 75.9 mg, 78%)을 수득하였다.To a 1,4-dioxane (3 mL) solution containing the minor adduct ( 7 g , 133.4 mg, 0.3 mmol) obtained in Example 10 was added H 3 PO 2 (164.2 μL, 5.0 equivalents, 50wt% in H 2 O) and Et 3 N (230.0 μL, was added to 5.5 eq.) was added AIBN (29.6 mg, 0.6 eq) to the reaction solution was refluxed for 10 minutes in 100 ℃ under an argon gas, and another 1 After refluxing under argon gas for a period of time, it was cooled to room temperature. The reaction solution was diluted with CH 2 Cl 2 (20 mL), and then saturated aqueous NH 4 Cl solution (10 mL) was added to shake. The organic layer was separated with a separatory funnel. The upper aqueous layer was washed with CH 2 Cl 2 And extracted twice more. The separated organic layers were combined and then treated with anhydrous MgSO 4 , filtered, and the solvent was removed using a rotary evaporator. The obtained residue was purified byprofessional column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 5/1 ) To give the title compound ( 3 g , 75.9 mg, 78%).
1H NMR (CDCl3, 400 MHz) δ 0.88 (t, J = 6.8 Hz, 3 H), 1.25 (bs, 12 H), 1.51-1.61 (m, 2 H), 2.46 (s, 3 H), 2.69 (t, J = 7.2 Hz, 2 H), 4.12 (s, 2 H), 7.37 (d, J = 8.0 Hz, 2 H) 7.75 (d, J = 8.0 Hz, 2 H). 1 H NMR (CDCl 3 , 400 MHz)? 0.88 (t, J = 6.8 Hz, 3 H), 1.25 (bs, 12 H), 1.51-1.61 2.69 (t, J = 7.2 Hz , 2 H), 4.12 (s, 2 H), 7.37 (d, J = 8.0 Hz, 2 H) 7.75 (d, J = 8.0 Hz, 2 H).
실시예Example 20: 1-( 20: 1- ( 메틸설포닐Methylsulfonyl )-6-) -6- 페닐헥산Phenyl hexane -2-온 (1-(One (1- ( MethylsulfonylMethylsulfonyl )-6-phenylhexan-2-one, 3h)의 제조) -6-phenylhexan-2-one, 3h)
실시예 11에서 수득한 잔테이트 부가물 (7h, 112.4 mg, 0.3 mmol)을 함유한 1,4-디옥산 (1,4-dioxane) (3 mL) 용액에 H3PO2 (164.2 μL, 5.0 당량, 50wt % in H2O) 및 Et3N (230.0 μL, 5.5 당량)을 가하고 아르곤 기체 하에서 100℃로 10분 동안 환류한 다음 반응 용액에 AIBN (29.6 mg, 0.6 당량)을 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류한 후 상온으로 냉각하였다. 반응 용액에 CH2Cl2 (20 mL)를 가하여 희석한 후 포화된 NH4Cl 수용액 (10 mL)을 가하여 흔들어 준 후 분액 깔대기로 유기층을 분리하고 상부의 수용액 층은 CH2Cl2 (10 mL)로 2회 더 추출하였다. 분리된 유기층을 전부 합한 후 무수 MgSO4로 처리하고 여과한 다음 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 2.5/1)로 정제하여 표제 화합물 (3h, 58.7 mg, 77%)을 수득하였다.H 3 PO 2 (164.2 μL, 5.0 mmol) was added to a 1,4-dioxane (3 mL) solution containing the minor adduct ( 7h , 112.4 mg, 0.3 mmol) obtained in Example 11 equivalents, 50wt% in H 2 O) and Et 3 N (230.0 μL, was added to 5.5 eq.) was added AIBN (29.6 mg, 0.6 eq) to the reaction solution was refluxed for 10 minutes in 100 ℃ under an argon gas, and another 1 After refluxing under argon gas for a period of time, it was cooled to room temperature. The reaction solution was diluted with CH 2 Cl 2 (20 mL), shaken with saturated aqueous NH 4 Cl solution (10 mL), and the organic layer was separated with a separatory funnel. The upper aqueous layer was washed with CH 2 Cl 2 ). ≪ / RTI > The separated organic layers were combined and treated with anhydrous MgSO 4 , filtered, and the solvent was removed by rotary evaporation. The residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 2.5 / 1 ) To give the title compound ( 3h , 58.7 mg, 77%).
1H NMR (CDCl3, 400 MHz) δ 1.59-1.72 (m, 4 H), 2.63 (t, J = 6.8 Hz, 2 H), 2.73 (t, J = 6.8 Hz, 2 H), 3.03 (s, 3 H), 3.99 (s, 2 H), 7.14-7.32 (m, 5 H). 1 H NMR (CDCl 3, 400 MHz) δ 1.59-1.72 (m, 4 H), 2.63 (t, J = 6.8 Hz, 2 H), 2.73 (t, J = 6.8 Hz, 2 H), 3.03 (s , 3 H), 3.99 (s, 2 H), 7.14-7.32 (m, 5 H).
실시예Example 21: 1-( 21: 1- ( 메틸설포닐Methylsulfonyl )) 운데칸Undecan -2-온 (1-(One (1- ( MethylsulfonylMethylsulfonyl )) undecanundecan -2--2- oneone , 3i)의 제조, 3i)
실시예 12에서 수득한 잔테이트 부가물 (7i, 110.6 mg, 0.3 mmol)을 함유한 1,4-디옥산 (1,4-dioxane) (3 mL) 용액에 H3PO2 (164.2 μL, 5.0 당량, 50wt % in H2O) 및 Et3N (230.0 μL, 5.5 당량)을 가하고 아르곤 기체 하에서 100℃로 10분 동안 환류한 다음 반응 용액에 AIBN (29.6 mg, 0.6 당량)을 첨가하고 다시 1시간 동안 아르곤 기체 하에서 환류한 후 상온으로 냉각하였다. 반응 용액에 CH2Cl2 (20 mL)를 가하여 희석한 후 포화된 NH4Cl 수용액 (10 mL)을 가하여 흔들어 준 후 분액 깔대기로 유기층을 분리하고 상부 수용액 층은 CH2Cl2 (10 mL)로 2회 더 추출하였다. 분리된 유기층을 전부 합한 후 무수 MgSO4로 처리하고 여과한 다음 회전 감압증발기로 용매를 제거하여 얻어진 잔류물을 속성 컬럼 크로마토그래피 (실리카젤: Merck 70-230, 이동상: 헥산/EtOAc = 3/1)로 정제하여 표제 화합물 (3i, 62.6 mg, 84%)을 수득하였다.H 3 PO 2 (164.2 μL, 5.0 mmol) was added to a 1,4-dioxane (3 mL) solution containing the zetate adduct ( 7i , 110.6 mg, 0.3 mmol) obtained in Example 12 equivalents, 50wt% in H 2 O) and Et 3 N (230.0 μL, was added to 5.5 eq.) was added AIBN (29.6 mg, 0.6 eq) to the reaction solution was refluxed for 10 minutes in 100 ℃ under an argon gas, and another 1 After refluxing under argon gas for a period of time, it was cooled to room temperature. The reaction solution was diluted with CH 2 Cl 2 (20 mL), and then saturated aqueous NH 4 Cl solution (10 mL) was added to shake. The organic layer was separated with a separatory funnel. The upper aqueous layer was washed with CH 2 Cl 2 And extracted twice more. The separated organic layers were combined and treated with anhydrous MgSO 4 , filtered, and the solvent was removed by rotary evaporation. The residue was purified by flash column chromatography (silica gel: Merck 70-230, mobile phase: hexane / EtOAc = 3/1 ) To give the title compound ( 3i , 62.6 mg, 84%).
1H NMR (CDCl3, 400 MHz) δ 0.88 (t, J = 7.4 Hz, 3 H), 1.26 (bs, 12 H), 1.53-1.68 (m, 2 H), 2.70 (t, J = 7.2 Hz, 2 H), 3.05 (s, 3 H), 4.02 (s, 2 H). 1 H NMR (CDCl 3, 400 MHz) δ 0.88 (t, J = 7.4 Hz, 3 H), 1.26 (bs, 12 H), 1.53-1.68 (m, 2 H), 2.70 (t, J = 7.2 Hz, 2 H), 3.05 (s, 3 H), 4.02 (s, 2 H).
Claims (8)
(ii) 하기 화학식 1의 잔테이트 화합물을 하기 화학식 2의 올레핀 화합물과 부가반응시켜 하기 화학식 7의 잔테이트 부가물을 수득하는 단계; 및
(iii) 하기 화학식 7의 잔테이트 부가물을 라디칼 환원반응시키는 단계를 포함하는 하기 화학식 3의 β-케토 설폰 화합물의 제조방법:
[화학식 4]
[화학식 5]
[화학식 6]
[화학식 1]
[화학식 2]
[화학식 7]
[화학식 3]
상기 식에서,
Xa는 -SC(=S)OEt이고,
R1은 C1-C6의 알킬기; 또는 C1-C6의 알킬기로 치환되거나 치환되지 않은 페닐이며,
R2는 C1-C6의 알킬기, 페닐, 벤질옥시, -OCOR3 또는 -R4COR5이고,
R3, R4 및 R5는 각각 독립적으로 C1-C6의 알킬기이다.(i) reacting 1,3-dichloroacetone represented by the following formula (4) with a sodium sulfinate compound represented by the following formula (5) and potassium O -ethylantoate represented by the following formula (6) sequentially at room temperature to obtain a 4- ;
(ii) subjecting a zwitterion compound of the formula (1) to an addition reaction with an olefin compound of the formula (2) to obtain a zirconate adduct of the formula (7); And
(iii) a step of subjecting a side-chain adduct of the following formula (7) to a radical reduction reaction to prepare a? -ketosulfone compound of the following formula
[Chemical Formula 4]
[Chemical Formula 5]
[Chemical Formula 6]
[Chemical Formula 1]
(2)
(7)
(3)
In this formula,
Xa is -SC (= S) OEt,
R 1 is a C 1 -C 6 alkyl group; Or phenyl which is unsubstituted or substituted by a C 1 -C 6 alkyl group,
R 2 is a C 1 -C 6 alkyl group, phenyl, benzyloxy, -OCOR 3 or -R 4 COR 5 ,
R 3 , R 4 and R 5 are each independently a C 1 -C 6 alkyl group.
R1은 메틸; 또는 메틸로 치환되거나 치환되지 않은 페닐이며,
R2는 n-펜틸, 페닐, 벤질옥시, 아세톡시 또는 메틸카보닐메틸인 제조방법.The method according to claim 1,
R 1 is methyl; Or phenyl unsubstituted or substituted by methyl,
Wherein R < 2 > is n-pentyl, phenyl, benzyloxy, acetoxy or methylcarbonylmethyl.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170089216A KR101943889B1 (en) | 2017-07-13 | 2017-07-13 | Process of preparing β-keto sulfones using xanthate compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170089216A KR101943889B1 (en) | 2017-07-13 | 2017-07-13 | Process of preparing β-keto sulfones using xanthate compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190007780A KR20190007780A (en) | 2019-01-23 |
KR101943889B1 true KR101943889B1 (en) | 2019-01-30 |
Family
ID=65276700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170089216A KR101943889B1 (en) | 2017-07-13 | 2017-07-13 | Process of preparing β-keto sulfones using xanthate compounds |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101943889B1 (en) |
-
2017
- 2017-07-13 KR KR1020170089216A patent/KR101943889B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
Organic Biomolecular Chemistry, Vol.4, pp.278-290, 2006* |
Organic Letters, Vol.5, No.10, pp.1645-1648, 2003* |
Also Published As
Publication number | Publication date |
---|---|
KR20190007780A (en) | 2019-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2665722B1 (en) | Process for the preparation of diol sulfones | |
Xia et al. | Copper (II)-catalyzed remote sulfonylation of aminoquinolines with sodium sulfinates via radical coupling | |
EP2665723B1 (en) | Process for the preparation of statins in the presence of base | |
KR101421862B1 (en) | Nitrogen-containing heterocyclic compound and method for producing same | |
JP2009530273A (en) | Method for producing sulfonyl chloride derivative | |
FI128424B (en) | Process for the preparation of arylsulfonylpropenenitriles by photocatalytic reactions | |
KR101943889B1 (en) | Process of preparing β-keto sulfones using xanthate compounds | |
JP5702595B2 (en) | Process for producing 2-chloro-3-trifluoromethylpyridine | |
JPWO2018194077A1 (en) | Method for producing pyridine compound | |
JP6741149B2 (en) | Sulfonic acid, carboxylic acid or their salts | |
RU2628287C2 (en) | Production of n-substituted sulfoximine pyridine n-oxides | |
EP2665721B1 (en) | Methyltetrazole sulfides and sulfones | |
JP2020537680A (en) | Process for producing herbicidal pyridadinone compounds | |
JP2009504721A (en) | Chemical process | |
JP2014019667A (en) | Heteroatom-containing 5-membered ring compound having monofluoromethyl group, and process for producing the same with c-f binding scission as key reaction | |
KR101621754B1 (en) | PROCESS OF PREPARING α-KETO (CYANOMETHYLENE)TRIPHENYLPHOSPHORANES USING XANTHATE COMPOUNDS | |
CZ304171B6 (en) | Process for preparing protected chiral sulfone-diols | |
KR102365411B1 (en) | Novel sulfonamide intermediates and processes for preparing silodosin using the same | |
PL231215B1 (en) | Process for the preparation of substituted azetidinones and intermediates for the synthesis thereof | |
TWI542578B (en) | Preparation of Benzyl Nicotinic Acid Benzyl Ester Derivatives | |
JP4857748B2 (en) | Quazepam manufacturing method | |
TWI705056B (en) | Process for the preparation of triazoles | |
JP2023155765A (en) | Method for producing amide compound | |
Sutar et al. | A study of base-catalyzed aldol reaction of trimethylsilyl enolates | |
JP2011256130A (en) | Method for producing carbamate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |